S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

argenx Stock Price, News & Analysis (NASDAQ:ARGX)

$435.79
-9.55 (-2.14%)
(As of 04:30 PM ET)
Compare
Today's Range
$435.24
$444.78
50-Day Range
$445.34
$514.01
52-Week Range
$333.07
$550.76
Volume
413,121 shs
Average Volume
250,614 shs
Market Capitalization
$25.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$547.11

argenx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.79 Rating Score
Upside/​Downside
24.9% Upside
$547.05 Price Target
Short Interest
Healthy
1.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of argenx in the last 14 days
Based on 21 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.76) to ($2.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

819th out of 949 stocks

Biological Products, Except Diagnostic Industry

142nd out of 161 stocks


ARGX stock logo

About argenx Stock (NASDAQ:ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Stock Price History

ARGX Stock News Headlines

Analyst Ratings for argenx
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Argenx drug meets surprise late-stage failure
Why Is Dutch Pharma Argenx Trading Lower Today?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
argenx SE ARGX
argenx SE (NASDAQ:ARGX) Q3 2023 Earnings Call Transcript
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
843
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$547.11
High Stock Price Target
$628.00
Low Stock Price Target
$435.00
Potential Upside/Downside
+22.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
19 Analysts

Profitability

Net Income
$-709,590,000.00
Pretax Margin
-52.69%

Debt

Sales & Book Value

Annual Sales
$445.27 million
Book Value
$50.79 per share

Miscellaneous

Free Float
57,643,000
Market Cap
$26.31 billion
Optionable
Optionable
Beta
0.79
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Timothy Van Hauwermeiren EMBA (Age 51)
    M.B.A., M.Sc., CEO & Executive Director
    Comp: $1.44M
  • Mr. Karl Gubitz (Age 53)
    Chief Financial Officer
  • Ms. Malini Moorthy (Age 53)
    General Counsel
  • Mr. Arjen Lemmen M.Sc. (Age 38)
    Vice President of Corporate Development & Strategy
  • Ms. Andria Wilk (Age 49)
    Global Head of Quality
  • Mr. Luc Truyen (Age 58)
    Chief Medical Officer
  • Ms. Karen Massey (Age 44)
    Chief Operating Officer
  • Mr. Filip Borgions
    VP & Global Head of Technical Operations
  • Mr. Peter Ulrichts (Age 43)
    Chief Scientific Officer
  • Ms. Beth DelGiacco
    VP and Global Head of Corporate Communications & Investor Relations

Should I Buy argenx Stock? ARGX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of argenx was last updated on Thursday, November 16, 2023 at 12:00 AM.

Pros

Here are some ways that investors could benefit from investing in argenx SE:

  • argenx SE is a biotechnology company that develops therapies for the treatment of autoimmune diseases, which is a growing market with high demand.
  • Recent developments in argenx SE's therapies have shown promising results in clinical trials, indicating potential for successful treatments.
  • argenx SE has formed strategic partnerships with major pharmaceutical companies, such as AbbVie and Janssen, which can provide financial support and expertise in drug development.
  • The company has a strong pipeline of innovative therapies in various stages of development, offering potential for future revenue growth.
  • argenx SE has a collaboration with IQVIA Holdings Inc. to provide safety systems and services, ensuring the safety and quality of its therapies.

Cons

Investors should be bearish about investing in argenx SE for these reasons:

  • Investing in biotechnology companies carries inherent risks, including the possibility of clinical trial failures or regulatory setbacks.
  • The competitive landscape in the biotechnology industry is intense, with many companies vying for market share and limited resources.
  • argenx SE's success heavily relies on the successful development and commercialization of its therapies, which may face challenges in the highly regulated healthcare industry.
  • Fluctuations in the stock market and investor sentiment can impact the stock price of argenx SE, potentially leading to volatility in investment returns.
  • Investors should carefully consider their risk tolerance and conduct thorough research before making investment decisions in argenx SE.














ARGX Stock Analysis - Frequently Asked Questions

Should I buy or sell argenx stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 sell rating, 2 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price target for 2024?

20 Wall Street research analysts have issued 12 month target prices for argenx's shares. Their ARGX share price targets range from $435.00 to $628.00. On average, they expect the company's stock price to reach $547.05 in the next twelve months. This suggests a possible upside of 24.9% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2023?

argenx's stock was trading at $378.83 at the beginning of 2023. Since then, ARGX stock has increased by 15.6% and is now trading at $438.07.
View the best growth stocks for 2023 here
.

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our ARGX earnings forecast
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its quarterly earnings data on Tuesday, October, 31st. The company reported ($1.25) earnings per share for the quarter, topping analysts' consensus estimates of ($1.48) by $0.23. The company earned $339.84 million during the quarter, compared to analysts' expectations of $310.06 million. argenx had a negative trailing twelve-month return on equity of 12.40% and a negative net margin of 22.70%. During the same period in the previous year, the company earned ($4.26) EPS.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

argenx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (8.40%), Artisan Partners Limited Partnership (4.79%), Jennison Associates LLC (2.56%), Massachusetts Financial Services Co. MA (0.98%), Morgan Stanley (0.94%) and RTW Investments LP (0.86%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ARGX) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -